What if I asked you to take 3/4 of the stomach, which is the size of a football, through a hole smaller than a dime. You would think I'm crazy. Have I lost my mind.What What am I talking about. Am I a magician. Am I pulling like a rabbit out of a hat or something like that.And that's actually what I thought 25 years ago when I started surgical residency. At that time you did a lot of surgeries with open abdominal incisions. You did laparottoies for traumas. You did laparottoies for emergency surgery to save ...

'They took shrapnel from my heart' – the magnets saving lives in Ukraine https://t.co/aSQ6IPPftP ...

Core Viewpoint - Teleflex Incorporated has successfully completed the acquisition of substantially all of the Vascular Intervention business from BIOTRONIK SE & Co. KG, enhancing its portfolio and global presence in the cath lab and peripheral intervention market [1][3][5]. Acquisition Details - The acquisition was finalized for a cash payment of €760 million, subject to certain adjustments [2]. - The Vascular Intervention business includes a comprehensive portfolio for coronary and peripheral interventions, featuring key products such as the Pantera™ Lux™ Drug-Coated Balloon Catheter and the Orsiro™ Mission Drug Eluting Stent [3][4]. Financial Outlook - The acquired products are expected to generate revenues of €177 million ($204 million) in the second half of 2025, with an anticipated €91 million ($105 million) for the fourth quarter of 2025 [5]. - From 2026 onwards, annual constant currency revenue growth of 6% or better is expected from the acquired products [5][6]. Strategic Implications - The acquisition will allow Teleflex to invest in the clinical trial program for Freesolve™, a sirolimus-eluting Resorbable Metallic Scaffold technology, with plans for a U.S. pivotal study [4]. - The integration of the Vascular Intervention business is anticipated to enhance Teleflex's innovation pipeline and position the company to leverage emerging technologies in the market [3][4].

Key Takeaways BSX gains MedSurg share via growth in Endoscopy, Urology and Neuromodulation product lines. MDT expands Surgical Robotics with Hugo RAS, now rolled out across 30 international markets. Both BSX and MDT see growth in emerging markets. Investors are increasingly eyeing the fast-growing MedSurg equipment space, which is projected to witness a compound annual growth rate (CAGR) of 9.54% from 2025 to 2030 (per Grand View Research). Two prominent companies with a strong foothold in this space are ...

Decision at the highest levels of appeal in the Medicare process establishes medical necessity of the ReWalk Exoskeleton for enabling paralyzed individuals to stand and walk in everyday environments.MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, June 24, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced the recent ruling by an Adminis ...

June 18, 2025 05:02 PM GMT Medical Technology | North America Off the Beaten Path In this note we flag each week a handful of news drops that we think may have been missed / piqued our interest. [EW, MDT] Real-World Data in EMEA Favoring SAVR vs. TAVR In Younger Patients: A new study in Italy suggests that SAVR may be associated with more favorable mortality outcomes in intermediate surgical risk patients than TAVR, with curves decently below from about 1 year onwards (see below), which in theory is negativ ...

June 12, 2025 02:21 PM GMT Mindray Bio-Medical | Asia Pacific M Update Takeaways from Investor Day This year's event was very well attended. The chairman shared the overall business strategy against the evolving policy/ geopolitical backdrop. The senior R&D team discussed the total solution strategy for AI integration and consumable sales. Mindray aspires to be a global top 10 medtech player. Key Takeaways Mi-Care: As Mindray's most well-established segment, Mindray launched its proprietary LLM model for cr ...

Recon Supply Named Exclusive U.S. Distributor of ReShape’s STIMEL-03, Lap-Band® 2.0 FLEX, and Full Product Portfolio to Reach U.S. Veterans and Active-Duty Service MembersIRVINE, Calif., June 12, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced the signing of an exclusive U.S. distribution agreement with Recon Supply. Through this new strategic partnership, Recon Supply will distribute ReShape’s cutti ...

10 June 2025 | 10:02AM PDT Insulet Corp. (PODD): 46th Annual Global Healthcare Conference — Key Takeaways Presenters: Ana Maria Chadwick (EVP, CFO) Bottom Line: The company reiterated its core strategic priorities (driving increased penetration in Type 1s, ramping adoption in the Type 2 population, and expanding internationally) as well as achieving at least 100bps of annual operating margin expansion. PODD shares were underperforming the S&P 500 by ~250bps (at the time of this note), mainly as investors de ...

WINTER SPRINGS, Fla., May 29, 2025 (GLOBE NEWSWIRE) -- Iradimed Corporation (NASDAQ: IRMD), a global leader in innovative medical devices for MRI environments, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its next-generation MRidium® 3870 IV Infusion Pump System. This advanced, MRI-compatible infusion pump extends Iradimed’s unique position as the world’s only supplier of non-magnetic MRI infusion pump devices, established with our first-generation device ...